Drug intelligence / Profile preview

HUM-223

Development stage: Preclinical
Modality: Small Molecules

Overview

HUM-223 is an experimental **small-molecule cannabigerol derivative** reported in preclinical research as having **anti-inflammatory and analgesic activity**. It appears to be a synthetic derivative of cannabigerol developed as a research-stage cannabinoid analog for the treatment of inflammatory conditions and pain. The precise molecular target or target selectivity has not been clearly established in the provided sources, so its mechanism is best described as an incompletely characterized cannabinoid-derived anti-inflammatory and analgesic small molecule evaluated in murine models.

Beyond the preview

Go deeper on HUM-223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUM-223.

Explore the full profile